Exemplos de uso de Time to onset em Inglês e suas traduções para o Português
{-}
-
Medicine
-
Colloquial
-
Official
-
Financial
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Official/political
The time to onset was 69.6 weeks.
For examples of the associated manifestations reported and a description of the time to onset, see section 4.4.
Time to Onset of Primary Symptom Relief hrs.
The primary efficacy endpoint was the time to onset of symptom relief using a visual analogue scale VAS.
Time to Onset of Symptom Relief-- Composite VAS hrs.
As pessoas também se traduzem
Observed significant andclinically relevant time to onset of thrombolytic therapy, 28± 12 minutes with the use of INR-POCT.
The time to onset of protection after commencing Truvada is unknown.
In the Phase III trials,the primary efficacy endpoint was time to onset of symptom relief using a visual analogue scale VAS.
Median time to onset was 1.1 months range: 0.0-10.4.
Hcv complicates the reconstitution of the immune system increases the risk of hepatotoxicity and reduces the time to onset of aids and death.
Median time to onset was 11.6 weeks range: 2.6-85.1.
The results were similar to patients with non-laryngeal attacks of HAE with respect to time to onset of symptom relief.
The time to onset of a mixed nutritional therapy ENT and PNT is controversial.
Relevant information(e.g. seriousness, severity,frequency, time to onset, reversibility of the AE as applicable) for the following safety concerns.
Median time to onset of these endocrinopathies was 1.5 months range: 0.0-10.1.
The objectives of this work are:to verify the adequacy of the quality indicators in nutritional therapy time to onset of nutritional therapy, time to achieve energy needs, caloric and protein adequacy.
Median time to onset of these endocrinopathies was 17.8 weeks range: 6.1-33.1.
Warning and precautions on the the risk of hypersensitivity including anaphylaxis or ADA development,with particular reference to symptoms, time to onset and severity.
Time to onset of motor block was significantly longer in Group 1 than in groups 2 and 3 p< 0.05.
We attribute this to the fact that important variables in this set, such as the cardiac arrest rhythm,the time of arrest and the time to onset of specialized CPR, were not included.
The time to onset of symptoms varied from one day to several months after starting treatment.
The following variables were evaluated and correlated with PTA recovery rates: age, gender, vertigo, tinnitus, initial degree of hearing loss,hearing in the contralateral ear, and time to onset of treatment.
The time to onset of symptoms varied from one day to several months after starting treatment.
Detailed information about the risk of haematological disorders(notably anaemia) associated with Victrelis,consisting of factual description of the haematological disorders in terms of frequency and time to onset and related clinical symptoms.
The time to onset action of cisatracurium was significantly lower p< 0.0001 in Group I 86.6± 14.3 seconds than in Group II 116.9± 11.6 seconds.
In patients who received ipilimumab 3 mg/kg monotherapy in MDX010-20, time to onset of moderate to severe or fatal(Grade 2-5) immune-related hepatotoxicity ranged from 3 to 9 weeks from the start of treatment.
Time to onset is usually around 3-6 weeks and the outcome in most cases is favourable upon discontinuation and after initiation of corticosteroid therapy.
Symptoms usually appeared within the first six weeks(median time to onset 11 days) of initiation of treatment with abacavir, although these reactions may occur at any time during therapy.
Time to onset of SRD was defined as a decrease of at least one point on the EDSS from a baseline EDSS score≥ 2 that was sustained for at least 6 months.
For patients who received ipilimumab 3 mg/kg monotherapy in MDX010-20, time to onset of moderate to very severe(Grade 2-4) immune-related endocrinopathy ranged from 7 to nearly 20 weeks from the start of treatment.